Todd C. Skaar
YOU?
Author Swipe
View article: Educational and Equity Implications of Biomarker Testing and Targeted Therapy Access in NSCLC: Insights from the NIH All of Us Research Program
Educational and Equity Implications of Biomarker Testing and Targeted Therapy Access in NSCLC: Insights from the NIH All of Us Research Program Open
Precision oncology in non-small cell lung cancer (NSCLC) depends on biomarker testing and access to targeted therapies. However, disparities in testing and treatment highlight critical educational needs for patients, providers, and health …
View article: The Pharmacogenomics Global Research Network Implementation Working Group: global collaboration to advance pharmacogenetic implementation.
The Pharmacogenomics Global Research Network Implementation Working Group: global collaboration to advance pharmacogenetic implementation. Open
Pharmacogenetics promises to optimize treatment-related outcomes by informing optimal drug selection and dosing based on an individual's genotype in conjunction with other important clinical factors. Despite significant evidence of genetic…
View article: Enrichment of Germline Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Pathogenic Variants in Patients With Solid Tumors: Evidence for Increased Cancer Risk
Enrichment of Germline Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Pathogenic Variants in Patients With Solid Tumors: Evidence for Increased Cancer Risk Open
Introduction Wide‐spread use of cystic fibrosis (CF) transmembrane conductance regulator (CFTR) modulators has resulted in a dramatic increase in life expectancy of people with CF. Historically, CFTR carrier status has been thought to be b…
View article: Initial-Care Medical and Prescription Costs for Incident Metastatic versus Nonmetastatic Colorectal Cancer
Initial-Care Medical and Prescription Costs for Incident Metastatic versus Nonmetastatic Colorectal Cancer Open
Colorectal cancer is a leading cause of cancer-related death and among the costliest cancers to treat in the United States. As advanced-stage diagnoses increase, the initial-care cost differences between metastatic (mCRC) and nonmetastatic…
View article: Evaluation of <i>CYP2C19</i> Clinical Decision Support Alerts to Guide P2Y<sub>12</sub> Inhibitor Prescribing
Evaluation of <i>CYP2C19</i> Clinical Decision Support Alerts to Guide P2Y<sub>12</sub> Inhibitor Prescribing Open
P2Y 12 inhibitor selection involves numerous factors, including CYP2C19 genetics, since evidence demonstrates reduced clopidogrel efficacy in patients with decreased or no function CYP2C19 variants. In 2020, Indiana University health embed…
View article: Return of Clinically Actionable Pharmacogenetic Results From Molecular Tumor Board <scp>DNA</scp> Sequencing Data: Workflow and Estimated Costs
Return of Clinically Actionable Pharmacogenetic Results From Molecular Tumor Board <span>DNA</span> Sequencing Data: Workflow and Estimated Costs Open
Pharmacogenetic testing can prevent severe toxicities from several oncology drug therapies; it also has the potential to improve the outcomes from supportive care drugs. Paired tumor and germline sequencing is increasingly common in oncolo…
View article: Functional analysis of G6PD variants associated with low G6PD activity in the All of Us Research Program
Functional analysis of G6PD variants associated with low G6PD activity in the All of Us Research Program Open
The glucose-6-phosphate dehydrogenase (G6PD) enzyme protects red blood cells against oxidative damage. Individuals with G6PD-impairing polymorphisms are at risk of hemolytic anemia from oxidative stressors. Prevention of G6PD deficiency-re…
View article: The Pharmacogenomics Global Research Network Implementation Working Group: global collaboration to advance pharmacogenetic implementation
The Pharmacogenomics Global Research Network Implementation Working Group: global collaboration to advance pharmacogenetic implementation Open
Pharmacogenetics promises to optimize treatment-related outcomes by informing optimal drug selection and dosing based on an individual’s genotype in conjunction with other important clinical factors. Despite significant evidence of genetic…
View article: Data from Cytochrome P450 oxidoreductase<i>, POR, </i>associated with severe paclitaxel-induced peripheral neuropathy in patients of European ancestry from ECOG-ACRIN E5103
Data from Cytochrome P450 oxidoreductase<i>, POR, </i>associated with severe paclitaxel-induced peripheral neuropathy in patients of European ancestry from ECOG-ACRIN E5103 Open
Purpose: Paclitaxel is a widely used anti-cancer therapeutic. Peripheral neuropathy is the dose-limiting toxicity and negatively impacts quality of life. Rare germline gene markers were evaluated for predicting severe taxane induced periph…
View article: Supplementary Table S1-S2 from Cytochrome P450 oxidoreductase<i>, POR, </i>associated with severe paclitaxel-induced peripheral neuropathy in patients of European ancestry from ECOG-ACRIN E5103
Supplementary Table S1-S2 from Cytochrome P450 oxidoreductase<i>, POR, </i>associated with severe paclitaxel-induced peripheral neuropathy in patients of European ancestry from ECOG-ACRIN E5103 Open
Supplemental table 1-Covariates analyses; Supplemental Table 2-Genotype frequency, variant allele frequency and Hardy-Weinberg Equilibrium (HWE) of variants in CYPs
View article: Supplementary Table S1-S2 from Cytochrome P450 oxidoreductase<i>, POR, </i>associated with severe paclitaxel-induced peripheral neuropathy in patients of European ancestry from ECOG-ACRIN E5103
Supplementary Table S1-S2 from Cytochrome P450 oxidoreductase<i>, POR, </i>associated with severe paclitaxel-induced peripheral neuropathy in patients of European ancestry from ECOG-ACRIN E5103 Open
Supplemental table 1-Covariates analyses; Supplemental Table 2-Genotype frequency, variant allele frequency and Hardy-Weinberg Equilibrium (HWE) of variants in CYPs
View article: Development of a Multifaceted Program for Pharmacogenetics Adoption at an Academic Medical Center: Practical Considerations and Lessons Learned
Development of a Multifaceted Program for Pharmacogenetics Adoption at an Academic Medical Center: Practical Considerations and Lessons Learned Open
In 2019, Indiana University launched the Precision Health Initiative to enhance the institutional adoption of precision medicine, including pharmacogenetics (PGx) implementation, at university‐affiliated practice sites across Indiana. The …
View article: Implementing a pragmatic clinical trial to tailor opioids for chronic pain on behalf of the <scp>IGNITE ADOPT PGx</scp> investigators
Implementing a pragmatic clinical trial to tailor opioids for chronic pain on behalf of the <span>IGNITE ADOPT PGx</span> investigators Open
Chronic pain is a prevalent condition with enormous economic burden. Opioids such as tramadol, codeine, and hydrocodone are commonly used to treat chronic pain; these drugs are activated to more potent opioid receptor agonists by the hepat…
View article: Supplementary Table S5 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
Supplementary Table S5 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11 Open
Supplementary Table S5: Association between clinicopathological variables and treatment discontinuation due to AIMSS.
View article: Data from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
Data from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11 Open
Purpose:Aromatase inhibitor (AI)–associated musculoskeletal symptoms (AIMSS) are common and frequently lead to AI discontinuation. SNPs in candidate genes have been associated with AIMSS and AI discontinuation. E1Z11 is a prospective cohor…
View article: Supplementary Table S4 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
Supplementary Table S4 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11 Open
Supplementary Table S4: HAQ Scores at different time points (n=970).
View article: Supplementary Table S6 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
Supplementary Table S6 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11 Open
Supplementary Table S6: Allele frequency and Hardy-Weinberg equilibrium test result, by patient cohort.
View article: Supplementary Table S5 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
Supplementary Table S5 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11 Open
Supplementary Table S5: Association between clinicopathological variables and treatment discontinuation due to AIMSS.
View article: Supplementary Table S3 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
Supplementary Table S3 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11 Open
Supplementary Table S3: Off Treatment Reason.
View article: Supplementary Table S3 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
Supplementary Table S3 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11 Open
Supplementary Table S3: Off Treatment Reason.
View article: Supplementary Table S6 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
Supplementary Table S6 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11 Open
Supplementary Table S6: Allele frequency and Hardy-Weinberg equilibrium test result, by patient cohort.
View article: Supplementary Table S1 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
Supplementary Table S1 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11 Open
Supplementary Table S1: Representativeness of Study Participants
View article: Supplementary Table S2 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
Supplementary Table S2 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11 Open
Supplementary Table S2: All Grades Treatment Related Toxicities (CTCAE v4).
View article: Supplementary Table S2 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
Supplementary Table S2 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11 Open
Supplementary Table S2: All Grades Treatment Related Toxicities (CTCAE v4).
View article: Data from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
Data from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11 Open
Purpose:Aromatase inhibitor (AI)–associated musculoskeletal symptoms (AIMSS) are common and frequently lead to AI discontinuation. SNPs in candidate genes have been associated with AIMSS and AI discontinuation. E1Z11 is a prospective cohor…
View article: Supplementary Table S1 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
Supplementary Table S1 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11 Open
Supplementary Table S1: Representativeness of Study Participants
View article: Supplementary Table S4 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
Supplementary Table S4 from A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11 Open
Supplementary Table S4: HAQ Scores at different time points (n=970).
View article: Rationale and design for a pragmatic randomized trial to assess <scp>gene‐based</scp> prescribing for <scp>SSRIs</scp> in the treatment of depression
Rationale and design for a pragmatic randomized trial to assess <span>gene‐based</span> prescribing for <span>SSRIs</span> in the treatment of depression Open
Specific selective serotonin reuptake inhibitors (SSRIs) metabolism is strongly influenced by two pharmacogenes, CYP2D6 and CYP2C19 . However, the effectiveness of prospectively using pharmacogenetic variants to select or dose SSRIs for de…
View article: A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11 Open
Purpose: Aromatase inhibitor (AI)–associated musculoskeletal symptoms (AIMSS) are common and frequently lead to AI discontinuation. SNPs in candidate genes have been associated with AIMSS and AI discontinuation. E1Z11 is a prospective coho…